PMID- 10765930
OWN - NLM
STAT- MEDLINE
DCOM- 20000518
LR  - 20161124
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 43
IP  - 4
DP  - 2000 Apr
TI  - Serum matrix metalloproteinase 3 as a predictor of the degree of joint 
      destruction during the six months after measurement, in patients with early 
      rheumatoid arthritis.
PG  - 852-8
AB  - OBJECTIVE: To evaluate whether matrix metalloproteinase 3 (MMP-3), a proteinase 
      that is expressed in rheumatoid synovial tissue and shows potent activity in 
      degrading the proteoglycan of cartilage, plays a pivotal role in the joint 
      destruction seen in early rheumatoid arthritis (RA). METHODS: In a prospective 
      study of patients with early RA, the relationship between the serum concentration 
      of MMP-3, as determined by a sandwich enzyme immunoassay system, and the 
      progression of joint destruction in patients with early RA, as measured by the 
      Larsen radiologic score, was investigated. RESULTS: Serum MMP-3 levels were 
      elevated in the RA patients compared with healthy controls, not only in the late 
      stage, but also in the early stage of the disease in patients whose duration of 
      RA was <4 months. The serum MMP-3 level at entry into the study had a strong 
      correlation with the Larsen score at 6 months and 12 months after entry (r = 0.58 
      and r = 0.49, respectively). Similarly, the serum MMP-3 level at 12 months and 24 
      months after entry showed a positive association with the Larsen score in the 
      subsequent 6-12 months. Suppression of the serum MMP-3 level in the first year 
      led to a decline in joint damage in the second year. CONCLUSION: The serum 
      concentration of MMP-3 is a useful marker for predicting bone damage in the early 
      stage of RA, and the suppression of MMP-3 production may be an effective 
      therapeutic approach for patients with early RA.
FAU - Yamanaka, H
AU  - Yamanaka H
AD  - Institute of Rheumatology, Tokyo Women's Medical University, Japan.
FAU - Matsuda, Y
AU  - Matsuda Y
FAU - Tanaka, M
AU  - Tanaka M
FAU - Sendo, W
AU  - Sendo W
FAU - Nakajima, H
AU  - Nakajima H
FAU - Taniguchi, A
AU  - Taniguchi A
FAU - Kamatani, N
AU  - Kamatani N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Biomarkers)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
CIN - Arthritis Rheum. 2000 Nov;43(11):2614-5. PMID: 11083293
CIN - Arthritis Rheum. 2001 Dec;44(12):2940-1. PMID: 11762959
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*blood
MH  - Biomarkers/blood
MH  - Female
MH  - Humans
MH  - Joint Diseases/*blood/diagnostic imaging
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Prospective Studies
MH  - Radiography
MH  - Time Factors
EDAT- 2000/04/15 09:00
MHDA- 2000/05/20 09:00
CRDT- 2000/04/15 09:00
PHST- 2000/04/15 09:00 [pubmed]
PHST- 2000/05/20 09:00 [medline]
PHST- 2000/04/15 09:00 [entrez]
AID - 10.1002/1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7 [doi]
PST - ppublish
SO  - Arthritis Rheum. 2000 Apr;43(4):852-8. doi: 
      10.1002/1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7.